Becton Dickinson and Co (NYSE:BDX) Shares Acquired by Cardinal Capital Management

Cardinal Capital Management lifted its position in shares of Becton Dickinson and Co (NYSE:BDX) by 0.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,996 shares of the medical instruments supplier’s stock after purchasing an additional 50 shares during the quarter. Becton Dickinson and accounts for approximately 1.5% of Cardinal Capital Management’s portfolio, making the stock its 24th largest holding. Cardinal Capital Management’s holdings in Becton Dickinson and were worth $5,311,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of BDX. Price T Rowe Associates Inc. MD grew its stake in Becton Dickinson and by 0.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 34,250,739 shares of the medical instruments supplier’s stock valued at $8,631,529,000 after acquiring an additional 131,536 shares during the period. Vanguard Group Inc. grew its stake in Becton Dickinson and by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock valued at $5,800,769,000 after acquiring an additional 520,350 shares during the period. Morgan Stanley grew its stake in Becton Dickinson and by 66.7% in the 2nd quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock valued at $1,231,621,000 after acquiring an additional 1,955,095 shares during the period. Northern Trust Corp grew its stake in Becton Dickinson and by 1.5% in the 2nd quarter. Northern Trust Corp now owns 3,271,013 shares of the medical instruments supplier’s stock valued at $824,327,000 after acquiring an additional 47,202 shares during the period. Finally, Bank of America Corp DE grew its stake in Becton Dickinson and by 4.1% in the 2nd quarter. Bank of America Corp DE now owns 2,901,319 shares of the medical instruments supplier’s stock valued at $731,162,000 after acquiring an additional 114,398 shares during the period. 84.23% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Claire Fraser sold 1,429 shares of Becton Dickinson and stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $243.26, for a total transaction of $347,618.54. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider James C. Lim sold 1,929 shares of Becton Dickinson and stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $252.01, for a total value of $486,127.29. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,249 shares of company stock worth $9,616,803. 0.12% of the stock is currently owned by corporate insiders.

Shares of BDX opened at $258.59 on Friday. Becton Dickinson and Co has a 52-week low of $208.62 and a 52-week high of $264.74. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84. The firm’s fifty day moving average is $254.23 and its two-hundred day moving average is $246.15. The stock has a market cap of $69.32 billion, a PE ratio of 22.73, a price-to-earnings-growth ratio of 1.64 and a beta of 1.12.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The company had revenue of $4.35 billion for the quarter, compared to analysts’ expectations of $4.37 billion. During the same quarter in the previous year, the company posted $2.91 EPS. The firm’s quarterly revenue was up 1.7% on a year-over-year basis. As a group, research analysts anticipate that Becton Dickinson and Co will post 11.68 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 9th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, September 6th. This represents a $3.08 annualized dividend and a yield of 1.19%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

A number of equities research analysts recently issued reports on the stock. Morgan Stanley lifted their price target on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 16th. Piper Jaffray Companies dropped their price target on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Raymond James lifted their price target on shares of Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research note on Friday, June 28th. Wells Fargo & Co lifted their price target on shares of Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a research note on Friday, September 6th. Finally, ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Five research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and has a consensus rating of “Buy” and a consensus target price of $266.55.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Systematic Risk

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.